All Updates

All Updates

icon
Filter
Funding
Trethera awarded USD 2 million grant from the National Cancer Institute
Precision Medicine
May 30, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 30, 2023

Trethera awarded USD 2 million grant from the National Cancer Institute

Funding

  • Drug discovery and development company Trethera received a USD 2 million Small Business Innovative Research (SBIR) grant from the National Cancer Institute. This brings the total funds raised to USD 11 million.

  • The grant will be used to conduct further biomarker evaluations to inform patient selection and dosing strategies for multiple types of difficult-to-treat cancers.

  • Trethera, a clinical-stage biopharmaceutical company, focuses on developing novel drugs that target nucleotide metabolism for the treatment of cancer and autoimmune diseases. Its lead asset, TRE-515, is an orally delivered therapeutic designed to inhibit deoxycytidine kinase, an enzyme involved in the nucleoside salvage pathway (helps to recycle and reuse certain building blocks found in the DNA and RNA)​. Trethera aims to inhibit rapid cell proliferation in tumor cells and aberrant activated lymphocytes (a type of immune cell in our body that has become abnormal and overactive), potentially offering a new therapeutic approach for cancer and autoimmune diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.